TXNDC17

Summary

TXNDC17 (thioredoxin domain containing 17, HGNC:28218) is a protein-coding gene on chromosome 17p13.1, encoding Thioredoxin domain-containing protein 17 (Q9BRA2). Disulfide reductase.

Enables peroxidase activity and protein-disulfide reductase [NAD(P)H] activity. Involved in tumor necrosis factor-mediated signaling pathway. Located in cytosol.

Source: NCBI Gene 84817 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 29 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_032731

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28218
Approved symbol	TXNDC17
Name	thioredoxin domain containing 17
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	MGC14353, TRP14
Ensembl gene	ENSG00000129235
Ensembl biotype	protein_coding
OMIM	616967
Entrez	84817

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 5 protein_coding, 5 protein_coding_CDS_not_defined, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000250101, ENST00000570330, ENST00000571029, ENST00000571957, ENST00000573792, ENST00000574429, ENST00000574734, ENST00000574838, ENST00000576020, ENST00000577146, ENST00000939769, ENST00000939770

RefSeq mRNA: 1 — MANE Select: NM_032731 NM_032731

CCDS: CCDS11077

Canonical transcript exons

ENST00000250101 — 4 exons

Exon	Start	End
ENSE00000905317	6641060	6641227
ENSE00001204349	6642951	6644541
ENSE00003482800	6642249	6642324
ENSE00003491194	6641753	6641834

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 99.59.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 107.1867 / max 1059.0840, expressed in 1827 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159058	66.1614	1823
159055	27.1551	1817
159056	7.3458	1741
159057	6.3643	1684
159054	0.1601	84

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.59	gold quality
lower esophagus mucosa	UBERON:0035834	99.35	gold quality
esophagus mucosa	UBERON:0002469	99.16	gold quality
mucosa of transverse colon	UBERON:0004991	99.00	gold quality
oocyte	CL:0000023	98.99	gold quality
oral cavity	UBERON:0000167	98.80	gold quality
ileal mucosa	UBERON:0000331	98.64	gold quality
pharyngeal mucosa	UBERON:0000355	98.62	gold quality
kidney epithelium	UBERON:0004819	98.36	gold quality
esophagus squamous epithelium	UBERON:0006920	98.33	gold quality
duodenum	UBERON:0002114	98.13	gold quality
colonic mucosa	UBERON:0000317	98.10	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.96	gold quality
rectum	UBERON:0001052	97.88	gold quality
jejunal mucosa	UBERON:0000399	97.70	gold quality
upper arm skin	UBERON:0004263	97.55	gold quality
right adrenal gland	UBERON:0001233	97.48	gold quality
adult mammalian kidney	UBERON:0000082	97.42	gold quality
right adrenal gland cortex	UBERON:0035827	97.23	gold quality
islet of Langerhans	UBERON:0000006	97.17	gold quality
body of stomach	UBERON:0001161	97.15	gold quality
left adrenal gland	UBERON:0001234	97.14	gold quality
nasal cavity epithelium	UBERON:0005384	97.12	gold quality
body of pancreas	UBERON:0001150	97.08	gold quality
left adrenal gland cortex	UBERON:0035825	97.04	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	97.02	gold quality
secondary oocyte	CL:0000655	96.97	gold quality
gingiva	UBERON:0001828	96.93	gold quality
right lobe of liver	UBERON:0001114	96.90	gold quality
adrenal cortex	UBERON:0001235	96.77	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-6653	yes	1477.69
E-HCAD-1	yes	282.19
E-CURD-114	yes	77.31
E-ANND-3	yes	19.05
E-MTAB-10042	yes	7.16
E-MTAB-8495	no	1655.57
E-GEOD-86618	no	1041.55
E-MTAB-7303	no	627.86

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

78 targeting TXNDC17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-137-3P	99.87	74.74	2401
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-4677-5P	99.70	70.09	1940

Literature-anchored findings (GeneRIF, showing 9)

• TRP14 is a thioredoxin-related protein with roles in tumor necrosis factor-alpha signaling pathways (PMID:14607843)
• TRP14 is a thioredoxin-related protein of 14 kDa (PMID:14607844)
• Data report the crystal structure of human thioredoxin-related protein 14 determined at 1.8-angstrom resolution. (PMID:15355959)
• LC8 binds IkappaBalpha in a redox-dependent manner and thereby prevents its phosphorylation by IKK. TRP14 contributes to this inhibitory activity by maintaining LC8 in a reduced state. (PMID:18579519)
• The oxidoreductase activities of TRP14 thereby complement those of Trx1 and must therefore be considered for the full understanding of enzymatic control of cellular thiols and nitrosothiols. (PMID:24778250)
• TXNDC17, through participation of BECN1, induces autophagy and consequently results in paclitaxel resistance in ovarian cancer (PMID:25607466)
• Cellular S-denitrosylases: Potential role and interplay of Thioredoxin, TRP14, and Glutaredoxin systems in thiol-dependent protein denitrosylation. (PMID:33359085)
• TRP14 is the rate-limiting enzyme for intracellular cystine reduction and regulates proteome cysteinylation. (PMID:38811853)
• In-Depth Proteomic Analysis of Paraffin-Embedded Tissue Samples from Colorectal Cancer Patients Revealed TXNDC17 and SLC8A1 as Key Proteins Associated with the Disease. (PMID:39441737)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	txndc17	ENSDARG00000058079
mus_musculus	Txndc17	ENSMUSG00000020803
rattus_norvegicus	Txndc17	ENSRNOG00000083034
drosophila_melanogaster	cl	FBGN0000318
drosophila_melanogaster	CG3939	FBGN0040396
caenorhabditis_elegans		WBGENE00022188

Protein

Protein identifiers

Thioredoxin domain-containing protein 17 — Q9BRA2 (reviewed: Q9BRA2)

Alternative names: 14 kDa thioredoxin-related protein, Protein 42-9-9, Thioredoxin-like protein 5

All UniProt accessions (5): Q9BRA2, A0A140VJY7, I3L0K2, I3L2R6, I3L3M7

UniProt curated annotations — full annotation on UniProt →

Function. Disulfide reductase. May participate in various redox reactions through the reversible oxidation of its active center dithiol to a disulfide and catalyze dithiol-disulfide exchange reactions. Modulates TNF signaling and NF-kappa-B activation. Has peroxidase activity and may contribute to the elimination of cellular hydrogen peroxide.

Subunit / interactions. Interacts with TRXR1 and DYNLL1/DNCL1.

Subcellular location. Cytoplasm.

Tissue specificity. Ubiquitously expressed in cell lines.

Post-translational modifications. The oxidized protein is reduced by TRXR1.

Similarity. Belongs to the thioredoxin family.

RefSeq proteins (1): NP_116120* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010357	TXNDC17_dom	Domain
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR045108	TXNDC17-like	Family

Pfam: PF06110

Enzyme classification (BRENDA):

• EC 1.8.1.6 — cystine reductase (BRENDA: 9 organisms, 7 substrates, 9 inhibitors, 5 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
L-CYSTINE	0.0008–0.9	3

UniProt features (24 total): helix 7, strand 5, mutagenesis site 2, active site 2, site 2, initiator methionine 1, chain 1, turn 1, domain 1, modified residue 1, disulfide bond 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1WOU	X-RAY DIFFRACTION	1.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BRA2-F1	95.89	0.96

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4): 43 (nucleophile); 46 (nucleophile); 44 (contributes to redox potential value); 45 (contributes to redox potential value)

Post-translational modifications (1): 2

Disulfide bonds (1): 43–46

Mutagenesis-validated functional residues (2):

Position	Phenotype
46	loss of peroxidase activity.
43	loss of peroxidase activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 161 (showing top): GOBP_RESPONSE_TO_PEPTIDE, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, GOBP_CELLULAR_RESPONSE_TO_TOXIC_SUBSTANCE, GOBP_DETOXIFICATION, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, GOBP_TUMOR_NECROSIS_FACTOR_MEDIATED_SIGNALING_PATHWAY, RYTTCCTG_ETS2_B, GOMF_ANTIOXIDANT_ACTIVITY, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PEROXIDE_AS_ACCEPTOR, GOBP_RESPONSE_TO_TOXIC_SUBSTANCE, GOBP_RESPONSE_TO_TUMOR_NECROSIS_FACTOR, GOMF_DISULFIDE_OXIDOREDUCTASE_ACTIVITY, MODULE_49

GO Biological Process (2): tumor necrosis factor-mediated signaling pathway (GO:0033209), cellular oxidant detoxification (GO:0098869)

GO Molecular Function (3): peroxidase activity (GO:0004601), protein-disulfide reductase [NAD(P)H] activity (GO:0047134), protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cytokine-mediated signaling pathway	1
cellular response to tumor necrosis factor	1
cellular detoxification	1
antioxidant activity	1
oxidoreductase activity, acting on peroxide as acceptor	1
protein-disulfide reductase activity	1
oxidoreductase activity, acting on a sulfur group of donors, NAD(P) as acceptor	1
binding	1
cytoplasm	1
extracellular vesicle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

916 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TXNDC17	TRPC7	Q9HCX4	772
TXNDC17	TXN	P10599	724
TXNDC17	TXNL1	O43396	688
TXNDC17	TXNRD1	Q16881	579
TXNDC17	NXN	Q6DKJ4	549
TXNDC17	MB	P02144	506
TXNDC17	F2R	P25116	463
TXNDC17	TXN2	Q99757	432
TXNDC17	NDUFAB1	O14561	423
TXNDC17	GLRX	P35754	404
TXNDC17	ATP5MK	Q96IX5	404
TXNDC17	NDUFS5	O43920	396
TXNDC17	ERCC6L2	Q5T890	395
TXNDC17	AKR1A1	P14550	394
TXNDC17	NDUFB6	O95139	389

IntAct

26 interactions, top by confidence:

A	B	Type	Score
EXOSC8	TXNDC17	psi-mi:“MI:0915”(physical association)	0.720
TXNDC17	EXOSC8	psi-mi:“MI:0915”(physical association)	0.720
RUFY1	TXNDC17	psi-mi:“MI:0915”(physical association)	0.560
TXNDC17	RUFY1	psi-mi:“MI:0915”(physical association)	0.560
INCA1	TXNDC17	psi-mi:“MI:0915”(physical association)	0.560
TINF2	TXNDC17	psi-mi:“MI:0915”(physical association)	0.510
	TK2	psi-mi:“MI:0915”(physical association)	0.400
Cct4		psi-mi:“MI:0914”(association)	0.350
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
PRNP	WDR91	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
LMNA	CLIC1	psi-mi:“MI:0914”(association)	0.350
TXNDC17	CLIC2	psi-mi:“MI:0914”(association)	0.350
VHL	TXNDC17	psi-mi:“MI:0915”(physical association)	0.000
EPB41	TXNDC17	psi-mi:“MI:0915”(physical association)	0.000
HLA-B	TXNDC17	psi-mi:“MI:0915”(physical association)	0.000
TXNDC17	TINF2	psi-mi:“MI:0915”(physical association)	0.000
TXNDC17	EXOSC8	psi-mi:“MI:0915”(physical association)	0.000
TXNDC17	INCA1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (71): TXNDC17 (Two-hybrid), TXNDC17 (Two-hybrid), NLRP5 (Co-fractionation), TXNDC17 (Co-fractionation), TXNDC17 (Co-fractionation), TXNDC17 (Co-fractionation), TXNDC17 (Affinity Capture-MS), TXNDC17 (Affinity Capture-MS), TXNDC17 (Affinity Capture-MS), TXNDC17 (Affinity Capture-RNA), INS (Biochemical Activity), OXT (Biochemical Activity), AVP (Biochemical Activity), DYNLL1 (Affinity Capture-MS), CFL1 (Affinity Capture-MS)

ESM2 similar proteins: A2VE14, A9CQL8, D3ZVR7, P22234, P51583, Q0VCJ8, Q0VD27, Q29RZ1, Q4R5H6, Q58CY6, Q5EA19, Q5F415, Q5H8A4, Q5NVN7, Q5R7S9, Q5RB59, Q5REA8, Q5RES2, Q5RFN0, Q5RKN4, Q5TM64, Q5VYX0, Q5XIC4, Q5ZIL9, Q5ZJB7, Q5ZMH6, Q67FW5, Q6AXQ0, Q6T311, Q86XW9, Q8BGB7, Q8BGR6, Q8BUH1, Q8BZI6, Q8MJJ1, Q8TBF2, Q8WWQ2, Q96MZ0, Q96NT3, Q9BRA2

Diamond homologs: A1L4T4, A2XCT8, A2Z7C4, A4HYT9, A7E4S9, A7Z3X7, A8N4R7, A8N4R8, A8WMD5, A8XHQ1, A8YMJ4, A9BVZ7, A9SCJ6, A9SDW6, A9SS00, A9VCM7, A9VFE2, B0JUK9, B0SFU6, B0SP94, B2VAA3, B3QG72, B7PRF6, C0NZU2, C3ZAH2, C4YCU0, C5WWY0, C5X1F5, C7Z9Z4, D3BH90, D5GE59, D7T737, E0W481, E3KY53, E9AIE8, E9EUE8, F6HDT7, F6QS54, F6W3G8, F7FKV1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

29 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	17
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
583807	NC_000017.10:g.(?6328760)(6616672_?)del	Pathogenic

SpliceAI

665 predictions. Top by Δscore:

Variant	Effect	Δscore
17:6641179:GGTTC:G	donor_gain	1.0000
17:6641188:G:GT	donor_gain	1.0000
17:6642242:C:CA	acceptor_gain	1.0000
17:6642247:A:AG	acceptor_gain	1.0000
17:6642247:AGTT:A	acceptor_gain	1.0000
17:6642248:G:GT	acceptor_gain	1.0000
17:6642248:GTT:G	acceptor_gain	1.0000
17:6642248:GTTG:G	acceptor_gain	1.0000
17:6641180:GTTC:G	donor_gain	0.9900
17:6641181:TTCT:T	donor_gain	0.9900
17:6641226:GG:G	donor_gain	0.9900
17:6641227:GG:G	donor_gain	0.9900
17:6641830:CCTTA:C	donor_gain	0.9900
17:6642247:AGTTG:A	acceptor_gain	0.9900
17:6642248:GTTGG:G	acceptor_gain	0.9900
17:6641271:G:GT	donor_gain	0.9800
17:6641750:A:G	acceptor_gain	0.9800
17:6641751:A:AG	acceptor_gain	0.9800
17:6641752:G:GG	acceptor_gain	0.9800
17:6641835:G:GG	donor_gain	0.9800
17:6642246:TA:T	acceptor_loss	0.9800
17:6642320:GAACA:G	donor_gain	0.9800
17:6642325:G:GG	donor_gain	0.9800
17:6641272:A:T	donor_gain	0.9700
17:6641352:TCCCC:T	donor_gain	0.9700
17:6641749:A:AG	acceptor_gain	0.9700
17:6642322:ACAG:A	donor_loss	0.9700
17:6642323:CAGT:C	donor_loss	0.9700
17:6642324:AG:A	donor_loss	0.9700
17:6642325:G:A	donor_loss	0.9700

AlphaMissense

809 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:6641206:T:A	W42R	0.997
17:6641206:T:C	W42R	0.997
17:6641208:G:C	W42C	0.996
17:6641208:G:T	W42C	0.996
17:6642302:C:A	P94H	0.996
17:6641209:T:C	C43R	0.994
17:6642301:C:T	P94S	0.994
17:6641219:G:A	C46Y	0.993
17:6641814:C:G	C69W	0.993
17:6642299:T:A	V93E	0.993
17:6641220:C:G	C46W	0.992
17:6642276:A:C	R85S	0.992
17:6642276:A:T	R85S	0.992
17:6642308:T:A	L96Q	0.992
17:6642308:T:C	L96P	0.991
17:6642301:C:A	P94T	0.990
17:6641203:A:C	S41R	0.989
17:6641205:C:A	S41R	0.989
17:6641205:C:G	S41R	0.989
17:6641219:G:T	C46F	0.989
17:6641812:T:C	C69R	0.989
17:6642271:T:C	F84L	0.989
17:6642272:T:C	F84S	0.989
17:6642273:C:A	F84L	0.989
17:6642273:C:G	F84L	0.989
17:6642302:C:G	P94R	0.989
17:6642311:T:C	L97P	0.989
17:6641180:G:A	G33D	0.988
17:6641209:T:A	C43S	0.988
17:6641210:G:C	C43S	0.988

dbSNP variants (sampled 300 via entrez): RS1000365108 (17:6644143 G>A), RS1000788226 (17:6639355 G>A,C), RS1001333311 (17:6644781 C>A), RS1001380977 (17:6640174 G>A), RS1001413623 (17:6639900 A>G), RS1001418441 (17:6642229 C>T), RS1001814482 (17:6641049 T>A,C,G), RS1003390218 (17:6640261 G>T), RS1003424728 (17:6642490 T>A), RS1004982556 (17:6642805 T>A), RS1005988543 (17:6641227 G>C,T), RS1006010955 (17:6639761 T>C,G), RS1006957550 (17:6640575 C>A,T), RS1007464220 (17:6640800 A>G), RS1007623682 (17:6642366 G>A,C)

Disease associations

OMIM: gene MIM:616967 | disease phenotypes: MIM:604393, MIM:615905

GenCC curated gene-disease

Mondo (2): Leber congenital amaurosis 4 (MONDO:0011458), developmental and epileptic encephalopathy, 25 (MONDO:0014392)

Orphanet (1): Non-specific early-onset epileptic encephalopathy (Orphanet:442835)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009617_2	LDL cholesterol levels x thiazide or thiazide-like diuretics use interaction	1.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004611	low density lipoprotein cholesterol measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C565778	Leber Congenital Amaurosis 4 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295935 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Vorinostat	increases expression	3
Tobacco Smoke Pollution	affects expression, decreases expression, increases expression	3
bisphenol A	decreases expression, increases expression	2
sodium arsenite	increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Valproic Acid	increases expression, increases methylation	2
Cadmium Chloride	increases expression	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenate	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
cobaltous chloride	decreases expression	1
ochratoxin A	increases expression	1
di-n-butylphosphoric acid	affects expression	1
K 7174	decreases expression	1
dimethylarsinous acid	decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
bisphenol AF	increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	affects response to substance	1
Atrazine	decreases expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	affects binding, increases reaction	1
Citrinin	increases expression	1
Dactinomycin	affects cotreatment, increases secretion	1
Diazinon	increases methylation	1
Diuron	decreases expression	1
Furaldehyde	affects cotreatment, increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4232644	Binding	Binding affinity to TXNDC17 cysteine residue in human 786-O cell soluble proteomic lysate at 5 uM incubated for 1 hr followed by cell lysis by IA-alkyne probe based isoTOP-ABPP analysis	Covalent inhibitors of nicotinamide N-methyltransferase (NNMT) provide evidence for target engagement challenges in situ. — Bioorg Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E2MX	HAP1 TXNDC17 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

14 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT06467344	PHASE1/PHASE2	RECRUITING	Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
NCT06789445	PHASE1/PHASE2	RECRUITING	A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
NCT00427180	Not specified	UNKNOWN	IRIS PILOT - Extended Pilot Study With a Retinal Implant System
NCT01864486	Not specified	COMPLETED	Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy
NCT02435940	Not specified	RECRUITING	Inherited Retinal Degenerative Disease Registry
NCT02670980	Not specified	COMPLETED	Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy
NCT04658251	Not specified	TERMINATED	Study of New Mutations in Cone Disorders
NCT05355415	Not specified	RECRUITING	Adaptive Optics Imaging of Outer Retinal Diseases
NCT06445322	Not specified	RECRUITING	Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
NCT07548944	Not specified	RECRUITING	Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance
NCT07102524	PHASE1/PHASE2	NOT_YET_RECRUITING	Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder
NCT04681781	Not specified	ENROLLING_BY_INVITATION	SLC13A5 Deficiency Natural History Study - Remote Only
NCT06144957	Not specified	ENROLLING_BY_INVITATION	SLC13A5 Deficiency Natural History Study - United States Only